O	0	5	Early
O	6	17	participant
O	17	18	-
O	18	26	reported
O	27	35	symptoms
O	36	38	as
O	39	49	predictors
O	50	52	of
O	53	62	adherence
O	63	65	to
B-intervention	66	77	anastrozole
O	78	80	in
O	81	84	the
O	85	98	International
O	99	105	Breast
O	106	112	Cancer
O	113	125	Intervention
O	126	133	Studies
O	134	136	II
O	136	137	.

O	138	149	Anastrozole
O	150	157	reduces
O	158	164	breast
O	165	171	cancer
O	172	176	risk
O	177	179	in
O	180	185	women
O	186	188	at
O	189	193	high
O	194	198	risk
O	198	199	,
O	200	203	but
O	204	216	implementing
O	217	227	preventive
O	228	235	therapy
O	236	238	in
O	239	247	clinical
O	248	256	practice
O	257	259	is
O	260	269	difficult
O	269	270	.

O	271	275	Here
O	275	276	,
O	277	279	we
O	280	288	evaluate
O	289	298	adherence
O	299	301	to
O	302	313	anastrozole
O	314	316	in
O	317	320	the
O	321	334	International
O	335	341	Breast
O	342	348	Cancer
O	349	361	Intervention
O	362	367	Study
O	368	369	(
O	369	373	IBIS
O	373	374	)
O	374	375	-
O	375	377	II
O	378	388	prevention
O	389	392	and
O	393	399	ductal
O	400	409	carcinoma
O	410	412	in
O	413	417	situ
O	418	419	(
O	419	423	DCIS
O	423	424	)
O	425	431	trials
O	431	432	,
O	433	436	and
O	437	440	its
O	441	452	association
O	453	457	with
O	458	463	early
O	464	472	symptoms
O	472	473	.

O	474	476	In
O	477	480	the
O	481	491	prevention
O	492	497	trial
O	497	498	,
B-total-participants	499	503	3864
O	504	518	postmenopausal
O	519	524	women
O	525	529	were
O	530	540	randomized
O	541	543	to
B-control	544	551	placebo
O	552	558	versus
O	559	570	anastrozole
O	570	571	.

O	572	573	A
O	574	579	total
O	580	582	of
B-total-participants	583	587	2980
B-eligibility	588	602	postmenopausal
I-eligibility	603	608	women
I-eligibility	609	613	with
I-eligibility	614	618	DCIS
O	619	623	were
O	624	634	randomized
O	635	637	to
B-control	638	647	tamoxifen
O	648	654	versus
O	655	666	anastrozole
O	666	667	.

O	668	677	Adherence
O	678	680	to
O	681	686	trial
O	687	697	medication
O	698	701	was
O	702	712	calculated
O	713	718	using
O	719	722	the
O	723	729	Kaplan
O	729	730	-
O	730	735	Meier
O	736	742	method
O	743	746	and
O	747	750	all
O	751	752	P
O	752	753	-
O	753	759	values
O	760	764	were
O	765	768	two
O	768	769	-
O	769	774	sided
O	774	775	.

O	776	778	In
O	779	782	the
O	783	793	prevention
O	794	799	trial
O	799	800	,
B-outcome	801	810	adherence
O	811	814	was
O	815	817	65
O	817	818	.
O	818	819	8
O	819	820	%
O	821	822	[
O	822	833	anastrozole
O	834	835	(
B-iv-bin-percent	835	837	65
I-iv-bin-percent	837	838	.
I-iv-bin-percent	838	839	7
I-iv-bin-percent	839	840	%
O	840	841	)
O	842	848	versus
O	849	856	placebo
O	857	858	(
B-cv-bin-percent	858	860	65
I-cv-bin-percent	860	861	.
I-cv-bin-percent	861	862	9
I-cv-bin-percent	862	863	%
O	863	864	)
O	864	865	;
O	866	868	HR
O	869	870	=
O	871	872	0
O	872	873	.
O	873	875	97
O	876	877	(
O	877	878	0
O	878	879	.
O	879	881	87
O	881	882	-
O	882	883	1
O	883	884	.
O	884	886	09
O	886	887	)
O	887	888	,
O	889	890	P
O	891	892	=
O	893	894	0
O	894	895	.
O	895	896	6
O	896	897	]
O	897	898	.

B-outcome	899	908	Adherence
O	909	912	was
O	913	918	lower
O	919	922	for
O	923	928	those
O	929	938	reporting
O	939	949	arthralgia
O	950	952	in
O	953	956	the
O	957	964	placebo
O	965	970	group
O	971	972	(
O	972	973	P
O	974	975	=
O	976	977	0
O	977	978	.
O	978	980	02
O	980	981	)
O	982	984	or
O	985	998	gynecological
O	999	1007	symptoms
O	1008	1010	in
O	1011	1014	the
O	1015	1026	anastrozole
O	1027	1032	group
O	1033	1034	(
O	1034	1035	P
O	1036	1037	=
O	1038	1039	0
O	1039	1040	.
O	1040	1043	003
O	1043	1044	)
O	1044	1045	,
O	1046	1054	compared
O	1055	1059	with
O	1060	1065	those
O	1066	1069	not
O	1070	1079	reporting
O	1080	1085	these
O	1086	1094	symptoms
O	1095	1097	at
O	1098	1099	6
O	1100	1106	months
O	1106	1107	.

O	1108	1110	In
O	1111	1114	the
O	1115	1119	DCIS
O	1120	1125	study
O	1125	1126	,
B-outcome	1127	1136	adherence
O	1137	1140	was
O	1141	1143	66
O	1143	1144	.
O	1144	1145	7
O	1145	1146	%
O	1147	1148	[
O	1148	1159	anastrozole
O	1160	1161	(
B-iv-bin-percent	1161	1163	67
I-iv-bin-percent	1163	1164	.
I-iv-bin-percent	1164	1165	5
I-iv-bin-percent	1165	1166	%
O	1166	1167	)
O	1168	1174	versus
O	1175	1184	tamoxifen
O	1185	1186	(
B-cv-bin-percent	1186	1188	65
I-cv-bin-percent	1188	1189	.
I-cv-bin-percent	1189	1190	8
I-cv-bin-percent	1190	1191	%
O	1191	1192	)
O	1192	1193	;
O	1194	1196	HR
O	1197	1198	=
O	1199	1200	1
O	1200	1201	.
O	1201	1203	06
O	1204	1205	(
O	1205	1206	0
O	1206	1207	.
O	1207	1209	94
O	1209	1210	-
O	1210	1211	1
O	1211	1212	.
O	1212	1214	20
O	1214	1215	)
O	1215	1216	,
O	1217	1218	P
O	1219	1220	=
O	1221	1222	0
O	1222	1223	.
O	1223	1224	4
O	1224	1225	]
O	1225	1226	.

B-outcome	1227	1230	Hot
I-outcome	1231	1238	flashes
O	1239	1243	were
O	1244	1254	associated
O	1255	1259	with
O	1260	1267	greater
O	1268	1277	adherence
O	1278	1280	in
O	1281	1284	the
O	1285	1296	anastrozole
O	1297	1300	arm
O	1301	1302	(
O	1302	1303	P
O	1304	1305	=
O	1306	1307	0
O	1307	1308	.
O	1308	1310	02
O	1310	1311	)
O	1311	1312	.

O	1313	1315	In
O	1316	1320	both
O	1321	1328	studies
O	1328	1329	,
O	1330	1338	symptoms
O	1339	1343	were
O	1344	1350	mostly
O	1351	1355	mild
O	1356	1358	or
O	1359	1369	moderately
O	1370	1376	severe
O	1376	1377	,
O	1378	1381	and
O	1382	1391	adherence
O	1392	1401	decreased
O	1402	1406	with
O	1407	1417	increasing
O	1418	1426	severity
O	1427	1430	for
O	1431	1435	most
O	1436	1444	symptoms
O	1444	1445	.

B-outcome	1446	1450	Drop
I-outcome	1450	1451	-
I-outcome	1451	1455	outs
O	1456	1460	were
O	1461	1468	highest
O	1469	1471	in
O	1472	1475	the
O	1476	1481	first
O	1482	1483	1
O	1483	1484	.
O	1484	1485	5
O	1486	1491	years
O	1492	1494	of
O	1495	1502	therapy
O	1503	1505	in
O	1506	1510	both
O	1511	1517	trials
O	1517	1518	.

O	1519	1521	In
O	1522	1525	the
O	1526	1530	IBIS
O	1530	1531	-
O	1531	1533	II
O	1534	1544	prevention
O	1545	1548	and
O	1549	1553	DCIS
O	1554	1560	trials
O	1560	1561	,
O	1562	1566	over
O	1567	1570	two
O	1570	1571	-
O	1571	1577	thirds
O	1578	1580	of
O	1581	1586	women
O	1587	1591	were
B-outcome	1592	1600	adherent
I-outcome	1601	1603	to
I-outcome	1604	1611	therapy
O	1611	1612	,
O	1613	1617	with
O	1618	1620	no
O	1621	1632	differences
O	1633	1635	by
O	1636	1645	treatment
O	1646	1652	groups
O	1652	1653	.

O	1654	1666	Participants
O	1667	1670	who
O	1671	1679	reported
O	1680	1688	specific
O	1689	1697	symptoms
O	1698	1700	in
O	1701	1704	the
O	1705	1709	IBIS
O	1709	1710	-
O	1710	1712	II
O	1713	1723	prevention
O	1724	1729	trial
O	1730	1733	had
O	1734	1735	a
O	1736	1741	small
O	1742	1745	but
O	1746	1757	significant
O	1758	1764	effect
O	1765	1767	on
O	1768	1777	adherence
O	1777	1778	,
O	1779	1784	which
O	1785	1797	strengthened
O	1798	1800	as
O	1801	1809	severity
O	1810	1819	increased
O	1819	1820	.

O	1821	1831	Strategies
O	1832	1834	to
O	1835	1842	promote
O	1843	1852	adherence
O	1853	1859	should
O	1860	1866	target
O	1867	1870	the
O	1871	1876	first
O	1877	1881	year
O	1882	1884	of
O	1885	1895	preventive
O	1896	1903	therapy
O	1903	1904	.
